Venous Thromboembolic Risk and Its Prevention in Hospitalized Medical Patients

ABSTRACT

In medical patients, the risk of venous thromboembolism (VTE) is substantially underestimated and prophylaxis is used far less than in surgical patients, reflecting the scarcity of evidence supporting antithrombotic therapy in nonsurgical settings. However, current consensus documents recommend assessment of all medical, as well as surgical, patients for thromboembolic risk and provide prophylaxis recommendations according to the risk level, determined by the presence of different clinical and molecular risk factors. Although long-term, underlying clinical and molecular risk factors also have a major impact on overall risk in medical patients; risk clearly varies with the type of medical condition. Myocardial infarction, stroke, and malignant disease are linked to a high rate of VTE; recent evidence highlights patients with cardiopulmonary disease as a distinct risk group. Despite skepticism in some quarters, high-quality evidence confirms the efficacy of unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH) in reducing asymptomatic deep vein thrombosis (DVT) in a broad spectrum of medical patients; further studies are required to clarify the effect on fatal pulmonary embolism (PE). Emerging data from the recent PRINCE and MEDENOX studies demonstrate that the LMWH enoxaparin provides effective and well-tolerated VTE prevention in patients with severe cardiopulmonary disease. Emerging evidence has led to a grade 1A recommendation for the use of thromboprophylaxis in these patients in the most recent consensus conference on thromboprophylaxis. Further studies, however, are required to clarify the optimal duration of prophylaxis in medical patients and to evaluate the potential role of outpatient prophylaxis. Accurate risk assessment and prompt implementation of appropriate prophylaxis, selected on the basis of evidence from well-designed controlled clinical trials, may reduce the future morbidity and mortality due to VTE in medical patients.

KEYWORD

Venous thrombosis - pulmonary embolism - medical patients - thromboprophylaxis - low-molecular-weight heparins

REFERENCES

• 1 Anderson F A, Wheeler H B, Goldberg R J. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study.  Arch Intern Med . 1991;  151 933-938
• 2 Prandoni P, Villalta S, Bagatelle P. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients.  Haematologica . 1997;  82 423-428
• 3 Bick R L. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism.  Drugs . 2000;  60 575-595
• 4 Sandler D A, Martin J F. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?.  J R Soc Med . 1989;  82 203-205
• 5 Mandelli V, Schmid C, Zogno C, Morpurgo M. "False negatives" and "false positives" in acute pulmonary embolism: a clinical-postmortem comparison.  Cardiologia . 1997;  42 205-210
• 6 Geerts W H, Heit J A, Clagett G P. Prevention of venous thromboembolism.  Chest . 2001;  119(Suppl 1) 132S-175S
• 7 Baglin T P, White K, Charles A. Fatal pulmonary embolism in hospitalized medical patients.  J Clin Pathol . 1997;  50 609-610
• 8 Goldhaber S Z, Savage D D, Garrison R I. Risk factors for pulmonary embolism-the Framingham study.  JAMA . 1983;  74 1023-1028
• 9 Anderson F A, Wheeler H B, Goldberg R. Physician practices in the prevention of venous thromboembolism.  Ann Intern Med . 1991;  115 591-595
• 10 Nicolaides A N, Breddin H K, Fareed J. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.  Int Angiol . 2001;  20 1-37
• 11 Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients.  BMJ . 1992;  305 567-574
• 12 Second Thromboembolic Risk Factors (THRiFT II) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients.  Phlebology . 1999;  13 87-97
• 13 Gensini G F, Prisco D, Falciani M. Identification of candidates for prevention of venous thromboembolism.  Semin Thromb Hemost . 1997;  23 55-67
• 14 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.  Arch Intern Med . 2000;  160 3415-3420
• 15 Cade J F. High risk of the critically ill for venous thromboembolism.  Crit Care Med . 1982;  10 448-450
• 16 Belch J J, Lowe G DO, Ward A G. Prevention of deep vein thrombosis in medical patients by low-dose heparin.  Scott Med J . 1981;  26 115-117
• 17 Anderson G M, Hull E. The effect of dicoumarol upon the mortality and incidence of thromboembolic complication of congestive heart failure.  Am Heart J . 1950;  39 697-702
• 18 Hirsh D R, Ingenito E P, Goldhaber S Z. Prevalence of deep venous thrombosis among patients in medical intensive care.  JAMA . 1995;  274 335-337
• 19 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient.  Semin Thromb Hemost . 1999;  25 173-182
• 20 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res . 2001;  102 V215-V224
• 21 Gladman D D, Urowitz M. Venous syndromes and pulmonary embolism in systemic lupus erythematosus.  Ann Rheum Dis . 1980;  39 340-343
• 22 Talbot R W, Heppel J, Dozois R R, Beart Jr W R. Vascular complications of inflammatory bowel disease.  Mayo Clin Proc . 1986;  61 140-145
• 23 Goodnough L T, Saito H, Manni A. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen.  Cancer . 1984;  54 1264-1268
• 24 Levine M N, Gent M, Hirsh J. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.  N Engl J Med . 1988;  318 404-407
• 25 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.  J Clin Oncol . 1991;  9 286-294
• 26 Pritchard K I, Paterson A HG, Paul N A. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.  J Clin Oncol . 1996;  14 2731-2737
• 27 Trottier S J, Veremakis C, O'Brien J, Auer A I. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial.  Crit Care Med . 1995;  23 52-59
• 28 Bertina R M, Koeleman B P, Köster T. Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
• 29 Laffen M, Tuddenham E. Assessing thrombotic risk.  BMJ . 1998;  317 520-523
• 30 Storti S, Crucitti P, Cina G. Risk factors and prevention of venous thromboembolism.  RAYS . 1996;  21 439-460
• 31 Rosendaal F R. Venous thrombosis: a multicausal disease.  Lancet . 1999;  353 1167-1173
• 32 Haas S. Prophylaxis thromboembolique: Quand?.  <~>Et pour combien de temps? Tribune Medicale . 1998;  16 4-5
• 33 Chapuis Y, Augereau B, Clergue F. Prophylaxie des thromboses veineuses postopératoires: recommandations de l'Assistance publique-Hôpitaux de Paris.  Sang Thromb Vaiss . 1995;  7 119-120
• 34 Gardlund B, for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases.  Lancet . 1996;  347 1357-1361
• 35 Bergmann J-F, Caulin C. Heparin prophylaxis in bedridden patients (Letter).  Lancet . 1996;  384 205-206
• 36 Lederle F A. Heparin prophylaxis for medical patients (Editorial)?.  Ann Intern Med . 1998;  128 768-770
• 37 Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis.  Ann Intern Med . 1982;  96 561-565
• 38 Francis C W, Ricotta J J, Evarts C M. Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip and knee arthroplasty.  Clin Orthop . 1988;  232 271-278
• 39 Gallus A S, Hirsh J, Tuttle R J. Small subcutaneous doses of heparin in prevention of venous thrombosis.  N Engl J Med . 1973;  288 545-550
• 40 Dahan R, Houlbert D, Caulin C. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial.  Haemostasis . 1986;  16 159-164
• 41 Mottier D, for the Geriatric Enoxaparin Study Group. Prophylaxis of deep venous thrombosis in medical geriatric patients (Abst).  Thromb Haemost . 1993;  69(Suppl) 1115
• 42 Lechler E, Schramm W, Flosbach C W. The PRIME study group. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin).  Haemostasis . 1996;  26(Suppl 2) 49-56
• 43 Bergmann J-F, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness.  Thromb Haemost . 1996;  76 529-534
• 44 Harenberg J, Roebruck P, Heene D L, for the Heparin Study in Internal Medicine Group. Subcutaneous low-molecular heparin versus standard heparin and the prevention of thromboembolism in medical inpatients.  Haemostasis . 1996;  26 127-139
• 45 Fraisse F, Holzapfel L, Couland J M. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.  Am J Respir Crit Care Med . 2000;  161 1109-1114
• 46 Mismetti P, Laporte-Simitsidis S, Tardy B. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials.  Thromb Haemost . 2000;  83 14-19
• 47 Samama M M, Cohen A T, Darmon J Y. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.  N Engl J Med . 1999;  341 793-800
• 48 Kleber F X, Witt C, Flosbach C W, and the PRINCE Study Group. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with severe cardiopulmonary disease (Abst).  Thromb Haemost . 1999;  (Suppl) 1552
• 49 Kleber F X, Flosbach C W, Koppenhagen K. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with hearth failure NYHA III/IV (PRINCE II study) (Abst 3265).  Circulation . 1999;  100(Suppl I) I-619